#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    IPEX syndrome Chronic cutaneous lupus erythematosus Leiomyosarcoma Chronic lymphocytic leukaemia recurrent Hypochromic anaemia Univentricular heart Adenocarcinoma pancreas Staphylococcal infection Allogenic stem cell transplantation Pustular psoriasis Immunodeficiency common variable Cognitive disorder Ovarian cancer stage IV Neuromyelitis optica spectrum disorder Optic glioma More trials…

    Learn about Rare Diseases

    Familial amyotrophic lateral sclerosis – Basic Information Retinitis pigmentosa – Treatment Ewing’s sarcoma recurrent Glomerulonephritis rapidly progressive Osteosarcoma metastatic – Trials in Disease Choroid melanoma – Trials in Disease Testicular leiomyosarcoma – Treatment Immunodeficiency congenital – Trials in Disease Cystic fibrosis – Trials in Disease Rhabdomyosarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Posaconazole Fosfomycin Inebilizumab Lu Ag09222 Sparsentan Trabectedin Thymalfasin Pyridoxine Alteplase Gfh925 Soya Oil, Purified Neostigmine Methylsulfate Evx-01 SAROGLITAZAR HEMIMAGNESIUM Nnc0194-0499 Pentixafor Gallium Ga-68 OMEGA-3-ACID ETHYL ESTERS 90 Fezolinetant Prednisolone Hydrocortisone Acetate More therapies…

    Learn about Your Condition

    Progressive multiple sclerosis Factor IX deficiency Nodular melanoma Dengue fever Marginal zone lymphoma Guttate psoriasis Incontinence Bacterial infection Rectosigmoid cancer Mast cell activation syndrome Vitamin D deficiency Agitation postoperative Anogenital warts Mite allergy Erosive oesophagitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myasthenia gravis

  • Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

    Recruiting

    3 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Remibrutinib
    Belgium France Germany Italy The Netherlands Poland +2

  • Study of Gefurulimab for Children and Teens with Generalized Myasthenia Gravis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Gefurulimab
    Poland

  • Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Fludarabine Phosphate
    • Human Normal Immunoglobulin (Iv)
    • Rapcabtagene Autoleucel
    France

  • Study on Efgartigimod for Early Treatment in Patients with Generalized Myasthenia Gravis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Efgartigimod Alfa
    Spain

  • Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Belgium Czechia France Germany Italy +3
Previous Page
1 2 3 4 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!